The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

By Mariam Sunny and Michael Erman Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a ...

Candida auris, a drug-resistant fungus that spreads through healthcare facilities, is gaining ground across the United States ...

During a tense White House press briefing1, 2026, Press Secretary Karoline Leavitt criticized CBS News and several other ...

Amy Acton’s service to retiring Gov. Mike DeWine gives her bipartisan credibility in a Republican state, but that service, leading Ohio’s pandemic response, also stirs charged emotions.

The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and ...

National Institutes of Health Director Jay Bhattacharya will step in as acting director of the Centers for Disease Control ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

Researchers identify genetic mutation in small group of people who developed the serious disorder after receiving the AstraZeneca or Johnson & Johnson vaccine.

The director of the National Institutes of Health, Dr. Jay Bhattacharya, will also take on the temporary role of acting director of the US Centers for Disease Control and Prevention, an administration ...

The co-author of the Great Barrington Declaration, which rebuked CDC’s response to the coronavirus pandemic, will oversee the nation’s leading public health agency.